20
Xenon anaesthesia Nick Harper

Xenon anaesthesia

Embed Size (px)

Citation preview

Page 1: Xenon anaesthesia

Xenon anaesthesiaNick Harper

Page 2: Xenon anaesthesia

Contents• History

• Anaesthetic properties

• Environmental impact

• Cost

• Advantages & potential for clinical use– Cardiovascular stability– Neuroprotection– Renal transplant

• Summary

Page 3: Xenon anaesthesia

1898

1939

1946

1951

Rectification of liquid air

•Ramsay & Travers

•-108.13C new gas discovered

•0.0000087%

•Xenon “stranger”

Page 4: Xenon anaesthesia
Page 5: Xenon anaesthesia

Xenon anaesthesia

1898

1939

1946

1951

1939 Anaesthetic properties discovered

Page 6: Xenon anaesthesia

Xenon anaesthesia

1946 Lawrence

Mice

1898

1939

1946

1951

1939 Anaesthetic properties discovered

Page 7: Xenon anaesthesia

Xenon anaesthesia

1946 Lawrence

Mice

1951 Cullen

Humans

1898

1939

1946

1951

1939 Anaesthetic properties discovered

Page 8: Xenon anaesthesia

• Gas at room temp

• Non volatile

• Non teratogenic

• Odourless

• MAC 63.1% (Nakata et al, 2001)

• Blood/gas partition coefficient 0.115

• Rapid emergence = 5mins (2X faster than Desflurane)

• NMDA (N2O, Ketamine)

• Analgesia (1.5X potency N2O)(Petersen-Felix, S. et al., 1998)

Page 9: Xenon anaesthesia

Anaesthetic agent Environmental impact

IsofluraneEnfluraneHalothane

Chlorinated hydrocarbonsOzone depleting

Emission banned from 2030

DesfluraneSevoflurane

Fluorinated hydrocarbonsGreenhouse gas capacity 10X Co2

Nitrous oxide Greenhouse gas capacity 230X Co2

Xenon None

Page 10: Xenon anaesthesia

CostXenon 10X cost of sevoflurane

• £6 - £12 per litre

• Xe uptake 3L/hour

• £30 theoretical cost for 60mins

• £100 actual cost

• Closed circuit• Low flow• Recycling

Page 11: Xenon anaesthesia

Advantages?

Page 12: Xenon anaesthesia

Cardiovascular stability• Xenon Vs Isoflurane (n=252)

• HR stability (P<0.05)

• arterial pressure stability (P<0.05)Wappler, F. et al., 2007

• Xenon vs Propofol (n=40 )

• ASA III/IV, known CAD

• Elective non-cardiac

• Improved myocardial performanceBaumert, J.H. et al., 2008

Page 13: Xenon anaesthesia

Ischaemia

Glutamate release

NMDA receptor activation

Apoptotic cascade

“excitotoxicity”

Neuroprotection

Page 14: Xenon anaesthesia

Neuroprotection

• Mouse neuronal-glial cell culture• LDH as index of damage

Wilhelm, S. et al., 2002

• Hippocampal brain slices• Propidium Iodide

Banks, P. et al., 2010

• Xenon – dose dependent neuroprotection

Page 15: Xenon anaesthesia

Neuroprotection

Hypoxic/ischaemic brain injury

1-6 per 1000 live births

Mortality 15-20%

25% of survivors are severely disabled

Page 16: Xenon anaesthesia

Neuroprotection

•Neonatal rats•Unilateral carotid ligation & 8% O2•50% Xenon +/- coolingHobbs, C. et al., 2008

Humans:80% neurological disability

1st baby treated April 2010

Page 17: Xenon anaesthesia

Renal protection

Renal transplant• Ischaemia reperfusion injury

• Delayed graft function, rejection, chronic nephropathy

Rat renal transplant model• Graft harvested 1-28 days for analysis

• 17 days control• 28 days (max) Xenon preconditioning (2hrs)

Zhao, H. & Ma, D., 2011

Page 18: Xenon anaesthesia

Summary• Fast, analgesic, non toxic, odourless, environmentally friendly

• High cardiovascular risk

• Neuroprotection

• Organ transplantation

Expensive!

• …”the perfect anaesthetic”

Page 19: Xenon anaesthesia

References (1)• Banks, P., Franks, N.P. & Dickinson, R. (2010)Competitive Inhibition at the Glycine Site of the N-Methyl-D-

Aspartate Receptor Mediates Xenon Neuroprotection against Hypoxia–Ischemia. Anesthesiology 112: 614 –622

• Baumert, J.H., Hein, M., Hecker, K.E., Satlow, S., Neef, P. & Rossaint, R. (2008) Xenon or propofol anaesthesia for patients at cardiovascular risk in non-cardiac surgery. British Journal of Anaesthesia 100 (5): 605–611

• Bein, B., Turowski, P., Renner, J., Hanss, R., Steinfath, M., Scholz, J. & Tonner, P.H. (2005) Comparison of xenon-based anaesthesia compared with total intravenous anaesthesia in high risk surgical patients. Anaesthesia 60: 960–967

• Hobbs, C,. Thoresen, M., Tucker, A., Aquilina, K., Chakkarapani, E. & Dingley, J. (2008) Xenon and Hypothermia Combine Additively, Offering Long-Term Functional and Histopathologic Neuroprotection After Neonatal Hypoxia/Ischemia. Stroke. 39(4): 1307-1313

• Homi, H.M., Yokoo, N., M.D., Ma, D., M.D., Warner, D.S., Franks, N.P., Maze, M. & Grocott, H.P. (2003) The Neuroprotective Effect of Xenon Administration during Transient Middle Cerebral Artery Occlusion in Mice. Anesthesiology. 99: 876 – 881

Page 20: Xenon anaesthesia

• Petersen-Felix, S., Luginbühl, M., Schnider, T.W., Curatolo, M., Arendt-Nielsen, L. & Zbinden, A.M. (1998) Comparison of the analgesic potency of xenon and nitrous oxide in humans evaluated by experimental pain. British Journal of Anaesthesia . 81(5): 742-747

• Wappler, F., Rossaint, R., Baumert, J., Scholz, J., Tonner, P.H., van Aken, H., Berendes, E., Klein, J,. Gommers, D., Hammerle, A., Franke, A., Hofmann, T. & Schulte Esch, J. Xenon Multicenter Study Research Group. (2007) Multicenter Randomized Comparison of Xenon andIsoflurane on Left Ventricular Function in PatientsUndergoing Elective Surgery. Anesthesiology. 106(3):463-471

• Wilhelm,S., Ma, D., M.D., Maze, M.& Franks, N.P. (2002) Effects of Xenon on In Vitro and In

Vivo Models of Neuronal Injury. Anesthesiology. 96: 1485–1491 • Zhao, H. & Ma, D. (2011) Xenon preconditioning protects renal graft against ischaemia –

reperfusion injury in rats. British Journal of Anaesthesia. 106(3): 428–446P

References (2)